Fig. 5: Antibodies targeting CD5L exhibit antitumor and antiangiogenic effects.
From: Overcoming adaptive resistance to anti-VEGF therapy by targeting CD5L
A Photographs of representative mice of control antibody and anti-CD5L antibody (H-447 and R-35) treated groups. Mice were treated intraperitoneally with either PBS or anti-CD5L antibody (10 mg/kg) starting on Day 8 after tumor injection until Day 35. B, C Tumor weight (B) and the number of tumor nodules (C). D CD31 immunofluorescence staining of tumors from control versus anti-CD5L antibody-treated groups. For statistical analysis, five randomly selected tumors per group were stained, and five random fields per tumor were scored. Scale bar = 100 µm. E, F Tube formation; scale bar = 500 µm (E) and cell migration; scale bar = 200 µm (F) of RF24 cells treated with either control antibody alone, control antibody + CD5L protein, or R-35 antibody + CD5L protein. Data represented as mean values ±  SEM determined by the Mann–Whitney test for B, C (n = 13 for control Ab; n = 7 for H-447 and R-35 antibodies respectively), ordinary one-way ANOVA Tukey’s multiple comparisons test for E and F and the two-sided Student’s t-test used for D; (n = 3 for D and E and 9 for F).
